Active ingredientUbrogepantCat. No. P-U002-001CAS 1374248-77-7Family · Pharmaceutical analytical standards
Ubrogepant
An oral antagonist of the receptor for CGRP, a neuropeptide released during a migraine attack: approved in the United States in December 2019 for the acute treatment of migraine, it was the first oral 'gepant' authorised there. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?CGRP was discovered in 1982 by studying the gene for calcitonin, a thyroid hormone: the same gene, with a different splicing of its RNA, produces this peptide in nerve cells.
Go to the active ingredient →Active ingredientUbrogepantCat. No. P-U002-001CAS 1374248-77-7
Isotopically labelledUbrogepant-d5Cat. No. P-U002-002
ImpurityUbrogepant Impurity 1Cat. No. P-U002-003CAS 1456803-37-4
ImpurityUbrogepant Impurity 2Cat. No. P-U002-004CAS 1375541-21-1
ImpurityUbrogepant Impurity 3Cat. No. P-U002-005
ImpurityUbrogepant Impurity 4Cat. No. P-U002-006
ImpurityUbrogepant Impurity 5Cat. No. P-U002-007
ImpurityUbrogepant N-Oxide 1Cat. No. P-U002-008
ImpurityUbrogepant N-Oxide 2Cat. No. P-U002-009No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.